275 related articles for article (PubMed ID: 24565018)
1. A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma.
Yuan J; Kashiwagi S; Reeves P; Nezivar J; Yang Y; Arrifin NH; Nguyen M; Jean-Mary G; Tong X; Uppal P; Korochkina S; Forbes B; Chen T; Righi E; Bronson R; Chen H; Orsulic S; Brauns T; Leblanc P; Scholler N; Dranoff G; Gelfand J; Poznansky MC
J Hematol Oncol; 2014 Feb; 7():15. PubMed ID: 24565018
[TBL] [Abstract][Full Text] [Related]
2. AMD3100 Augments the Efficacy of Mesothelin-Targeted, Immune-Activating VIC-008 in Mesothelioma by Modulating Intratumoral Immunosuppression.
Li B; Zeng Y; Reeves PM; Ran C; Liu Q; Qu X; Liang Y; Liu Z; Yuan J; Leblanc PR; Ye Z; Sluder AE; Gelfand JA; Brauns TA; Chen H; Poznansky MC
Cancer Immunol Res; 2018 May; 6(5):539-551. PubMed ID: 29511032
[TBL] [Abstract][Full Text] [Related]
3. Immuno-modulators enhance antigen-specific immunity and anti-tumor effects of mesothelin-specific chimeric DNA vaccine through promoting DC maturation.
Chen YL; Chang MC; Chiang YC; Lin HW; Sun NY; Chen CA; Sun WZ; Cheng WF
Cancer Lett; 2018 Jul; 425():152-163. PubMed ID: 29596890
[TBL] [Abstract][Full Text] [Related]
4. Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS.
de Goeje PL; Klaver Y; Kaijen-Lambers MEH; Langerak AW; Vroman H; Kunert A; Lamers CHJ; Aerts JGJV; Debets R; Hendriks RW
Front Immunol; 2018; 9():2034. PubMed ID: 30245692
[No Abstract] [Full Text] [Related]
5. Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy.
Dammeijer F; Lievense LA; Kaijen-Lambers ME; van Nimwegen M; Bezemer K; Hegmans JP; van Hall T; Hendriks RW; Aerts JG
Cancer Immunol Res; 2017 Jul; 5(7):535-546. PubMed ID: 28536100
[TBL] [Abstract][Full Text] [Related]
6. Cancer immunotherapy using irradiated tumor cells secreting heat shock protein 70.
Chang CL; Tsai YC; He L; Wu TC; Hung CF
Cancer Res; 2007 Oct; 67(20):10047-57. PubMed ID: 17942939
[TBL] [Abstract][Full Text] [Related]
7. Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human.
Aerts JGJV; de Goeje PL; Cornelissen R; Kaijen-Lambers MEH; Bezemer K; van der Leest CH; Mahaweni NM; Kunert A; Eskens FALM; Waasdorp C; Braakman E; van der Holt B; Vulto AG; Hendriks RW; Hegmans JPJJ; Hoogsteden HC
Clin Cancer Res; 2018 Feb; 24(4):766-776. PubMed ID: 29233904
[No Abstract] [Full Text] [Related]
8. Surgical cytoreduction restores the antitumor efficacy of a Listeria monocytogenes vaccine in malignant pleural mesothelioma.
Kennedy GT; Judy BF; Bhojnagarwala P; Moon EK; Fridlender ZG; Albelda SM; Singhal S
Immunol Lett; 2015 Jul; 166(1):28-35. PubMed ID: 25999306
[TBL] [Abstract][Full Text] [Related]
9. Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice.
Kim H; Gao W; Ho M
PLoS One; 2013; 8(11):e81919. PubMed ID: 24260587
[TBL] [Abstract][Full Text] [Related]
10. MtHsp70-CLIC1-pulsed dendritic cells enhance the immune response against ovarian cancer.
Yu W; Qu H; Cao G; Liu C; Deng H; Zhang Z
Biochem Biophys Res Commun; 2017 Dec; 494(1-2):13-19. PubMed ID: 29061300
[TBL] [Abstract][Full Text] [Related]
11. Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.
O'Hara M; Stashwick C; Haas AR; Tanyi JL
Immunotherapy; 2016; 8(4):449-60. PubMed ID: 26973126
[TBL] [Abstract][Full Text] [Related]
12. Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination.
Tan C; Dannull J; Nair SK; Ding E; Tyler DS; Pruitt SK; Lee WT
J Surg Res; 2013 Dec; 185(2):904-11. PubMed ID: 23891424
[TBL] [Abstract][Full Text] [Related]
13. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.
Le DT; Brockstedt DG; Nir-Paz R; Hampl J; Mathur S; Nemunaitis J; Sterman DH; Hassan R; Lutz E; Moyer B; Giedlin M; Louis JL; Sugar EA; Pons A; Cox AL; Levine J; Murphy AL; Illei P; Dubensky TW; Eiden JE; Jaffee EM; Laheru DA
Clin Cancer Res; 2012 Feb; 18(3):858-68. PubMed ID: 22147941
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells adenovirally-transduced with full-length mesothelin cDNA elicit mesothelin-specific cytotoxicity against pancreatic cancer cell lines in vitro.
Miyazawa M; Iwahashi M; Ojima T; Katsuda M; Nakamura M; Nakamori M; Ueda K; Naka T; Hayata K; Iida T; Yamaue H
Cancer Lett; 2011 Jun; 305(1):32-9. PubMed ID: 21397388
[TBL] [Abstract][Full Text] [Related]
15. Study on the mesothelin-specific cytotoxicity against epithelial ovarian cancer with full-length mesothelin cDNA-transduced dendritic cells.
Wang DH; Wu XH; Qian SM; Yao HR
Med Oncol; 2015 Apr; 32(4):116. PubMed ID: 25779534
[TBL] [Abstract][Full Text] [Related]
16. Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.
Hagemann UB; Ellingsen C; Schuhmacher J; Kristian A; Mobergslien A; Cruciani V; Wickstroem K; Schatz CA; Kneip C; Golfier S; Smeets R; Uran S; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Mumberg D; Ziegelbauer K; Cuthbertson AS
Clin Cancer Res; 2019 Aug; 25(15):4723-4734. PubMed ID: 31064781
[TBL] [Abstract][Full Text] [Related]
17. [Allogeneic dendritic cell vaccine pulsed with heat shocked tumor cell lysate can enhance antitumor immunity].
You J; Wang CL; Hao XS
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2785-90. PubMed ID: 18167273
[TBL] [Abstract][Full Text] [Related]
18. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.
Adusumilli PS; Cherkassky L; Villena-Vargas J; Colovos C; Servais E; Plotkin J; Jones DR; Sadelain M
Sci Transl Med; 2014 Nov; 6(261):261ra151. PubMed ID: 25378643
[TBL] [Abstract][Full Text] [Related]
19. A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity.
Yu X; Guo C; Yi H; Qian J; Fisher PB; Subjeck JR; Wang XY
Cancer Res; 2013 Apr; 73(7):2093-103. PubMed ID: 23333935
[TBL] [Abstract][Full Text] [Related]
20. Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer.
Anderson KG; Voillet V; Bates BM; Chiu EY; Burnett MG; Garcia NM; Oda SK; Morse CB; Stromnes IM; Drescher CW; Gottardo R; Greenberg PD
Cancer Immunol Res; 2019 Sep; 7(9):1412-1425. PubMed ID: 31337659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
